NAVB Navidea Biopharmaceuticals Inc.

0.14
0  1%
Previous Close 0.14
Open 0.14
Price To Book 13.8
Market Cap 25100917
Shares 181,890,700
Volume 628,119
Short Ratio 15.67
Av. Daily Volume 574,143

SEC filingsSee all SEC filings

  1. 8-K - Current report 181210936
  2. 8-K - Current report 181206396
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181172678
  4. 8-K - Current report 181166683
  5. 8-K - Current report 181155826

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved March 13, 2013.
Lymphoseek
Lymphatic-tissue tracing agent
Phase 3 - seeking partner to continue development
NAV4694
Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Approved June 13, 2014.
Lymphoseek
Head and Neck Cancer
Phase 1/2 initiated February 2017. Enrolling as of November 2017.
Lymphoseek
Rheumatoid arthritis

Latest News

  1. Navidea Biopharmaceuticals Announces Patent Extension for Lymphoseek®
  2. Edited Transcript of NAVB earnings conference call or presentation 7-Nov-18 9:30pm GMT
  3. Navidea Biopharmaceuticals Appoints Adam Cutler to Board of Directors
  4. Navidea Biopharmaceuticals Appoints Dr. Michael Rosol as Chief Medical Officer
  5. Navidea Biopharmaceuticals to Present at the 11th Annual LD Micro Event 2018
  6. Navidea Biopharmaceuticals Announces Presentation at the Radiological Society of North America (RSNA) 104th Scientific Assembly and Annual Meeting 2018
  7. Navidea Biopharmaceuticals Appoints Dr. Kathy Rouan to Board of Directors
  8. Recent Analysis Shows Aquantia, Ubiquiti Networks, Reliv' International, Permian Basin Royalty Trust, Patriot Transportation Holding, and Navidea Biopharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth
  9. Navidea: 3Q Earnings Snapshot
  10. Navidea Biopharmaceuticals Reports Third Quarter 2018 Financial Results
  11. Navidea Biopharmaceuticals Schedules Third Quarter 2018 Earnings Conference Call and Business Update
  12. Navidea Biopharmaceuticals Wins Dismissal of Platinum Litigation
  13. Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American
  14. Navidea Biopharmaceuticals to Present Data on the Manocept Platform at 2018 ACR Annual Meeting
  15. Navidea Biopharmaceuticals to Present at the 2018 BIO Investor Forum
  16. The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares
  17. Navidea Biopharmaceuticals Announces Acceptance into the National Institutes of Health Commercialization Accelerator Program
  18. Navidea Biopharmaceuticals Announces Closing of a $3 Million Private Placement
  19. Edited Transcript of NAVB earnings conference call or presentation 16-Aug-18 9:00pm GMT
  20. Navidea Biopharmaceuticals, Inc. to Host Earnings Call

SEC Filings

  1. 8-K - Current report 181210936
  2. 8-K - Current report 181206396
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181172678
  4. 8-K - Current report 181166683
  5. 8-K - Current report 181155826
  6. 8-K - Current report 181147547
  7. 8-K - Current report 181112170
  8. 8-K - Current report 181110709
  9. SC 13G - Statement of acquisition of beneficial ownership by individuals 181084245
  10. 8-K - Current report 181074189